Bad Tracleer data do Actelion good
This article was originally published in Scrip
Actelion's share price rose 2.41% to CHF89.15 after it unveiled negative trial results for the drug that provides the lion's share of its revenues. The Swiss firm's long-marketed Tracleer (bosentan) for the serious orphan disease pulmonary arterial hypertension has failed a Phase IV study measuring its ability to prolong the time before patients progress to first morbidity or mortality when they are already being treated with another drug, sildenafil.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.